Calidi Biotherapeutics Q4 2025 Earnings Report

Calidi Biotherapeutics EPS Results

• Actual EPS: $7.20
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Calidi Biotherapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Calidi Biotherapeutics Announcement Details

• Quarter: Q4 2025
• Date: 3/27/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors. Both programs leverage the company’s proprietary immune activator to induce rapid cytokine release and recruitment of innate and adaptive immune cells at the tumor site. Preclinical studies have also demonstrated potential for a systemically delivered candidate under investigation for metastatic solid tumors. In addition, Calidi maintains a pipeline of preclinical programs exploring prophylactic and therapeutic applications against viral pathogens.

Headquartered in South San Francisco, California, Calidi Biotherapeutics was founded to advance synthetic RNA-based immunomodulators into the clinic and is led by a management team with extensive experience in immuno-oncology drug development. The company collaborates with academic partners and contract manufacturing organizations to support clinical and regulatory activities. Calidi Biotherapeutics is publicly traded on the New York Stock Exchange under the symbol CLDI.